Cardio Diagnostics Holdings Inc (CDIO) is a pioneering biotechnology firm focused on enhancing cardiovascular health through innovative diagnostic solutions. The company utilizes state-of-the-art technology to equip healthcare professionals with vital tools for precise assessment and management of cardiovascular diseases, thereby improving patient outcomes. With a commitment to personalized medicine and a robust growth strategy, CDIO stands out as an attractive investment opportunity for institutional investors seeking to capitalize on advancements in the dynamic healthcare sector.
| Revenue (TTM) | 14,450 |
| Gross Profit (TTM) | 14,450 |
| EBITDA | $-6.08M |
| Operating Margin | -27950.00% |
| Return on Equity | -75.40% |
| Return on Assets | -44.10% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $2.51 |
| Price-to-Book | 0.81 |
| Price-to-Sales (TTM) | 407.57 |
| EV/Revenue | 56.77 |
| EV/EBITDA | -22.48 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -28.30% |
| Shares Outstanding | $2.96M |
| Float | $2.83M |
| % Insiders | 8.31% |
| % Institutions | 6.52% |
Volatility is currently expanding
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced that Atlas Healthcare Physicians (AHP) will cover Cardio Diagnostics' tests, Epi+Gen CHD™ and PrecisionCHD™.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will exhibit at four upcoming national benefits conferences.
AUSTIN, Texas, May 20, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CDIO and any ticker you trade — then tracks every position and per-strategy win rate.
